Coronavirus Disease 2019 (COVID-19) is a pandemic infection caused by a novel coronavirus named severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2). Patients present a complex clinical picture that, in severe cases, evolves to respiratory, hepatic, gastrointestinal, and neurological complications, and eventually death. The underlying pathophysiological mechanisms are complex and multifactorial and have been summarized as a hyperresponse of the immune system that originates an inflammatory/cytokine storm. In elderly patients, particularly in those with pre-existing cardiovascular, metabolic, renal, and pulmonary disorders, the disease is particularly severe, causing prolonged hospitalization at intensive care units (ICU) and an increased mortality rate. Curiously, the same populations have been described as more prone to a gut microbiota (GM) dysbiosis profile. Intestinal microflora plays a major role in many metabolic and immune functions of the host, including to educate and strengthen the immune system to fight infections, namely of viral origin. Notably, recent studies suggest the existence of GM dysbiosis in COVID-19 patients. This review article highlights the interplay between the triad GM dysbiosis–immune hyperresponse–inflammation in the individual resilience/fragility to SARS-CoV-2 infection and presents the putative impact of pharmacological and nutraceutical approaches on the triumvirate, with focus on GM.
The scientific knowledge already attained regarding the way severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infects human cells and the clinical manifestations and consequences for Coronavirus Disease 2019 (COVID-19) patients, especially the most severe cases, brought gut microbiota into the discussion. It has been suggested that intestinal microflora composition plays a role in this disease because of the following: (i) its relevance to an efficient immune system response; (ii) the fact that 5–10% of the patients present gastrointestinal symptoms; and (iii) because it is modulated by intestinal angiotensin-converting enzyme 2 (ACE2) (which is the virus receptor). In addition, it is known that the most severely affected patients (those who stay longer in hospital, who require intensive care, and who eventually die) are older people with pre-existing cardiovascular, metabolic, renal, and pulmonary diseases, the same people in which the prevalence of gut microflora dysbiosis is higher. The COVID-19 patients presenting poor outcomes are also those in which the immune system’s hyperresponsiveness and a severe inflammatory condition (collectively referred as “cytokine storm”) are particularly evident, and have been associated with impaired microbiota phenotype. In this article, we present the evidence existing thus far that may suggest an association between intestinal microbiota composition and the susceptibility of some patients to progress to severe stages of the disease.
Background/Objectives: “Low-fat” claims are defined by a fat threshold, with no requirements regarding the nutrients replacing fat. Reformulation often relies on refined starches and free sugars at the expense of dietary fiber. Thus, a low-fat (LF) product is not necessarily of good carbohydrate quality, a dimension that macronutrient-based classification fails to capture. Whether LF-derived poor carbohydrate quality is associated with organ-specific alterations across the gut–liver–kidney axis remains unknown. Methods: Male Wistar rats were fed for 24 weeks a purified LF diet, its ingredient-matched purified high-fat, high-sucrose counterpart (HF), or a whole-grain Chow reference of similar energy density. Carbohydrate quality was assessed using the carbohydrate-to-dietary fiber-to-free sugars ratio. Body weight and adiposity, glucose homeostasis, gut fermentation, and hepatic and renal functional and structural parameters were evaluated. Results: Only Chow met the 10:1:1 carbohydrate quality criterion. At a caloric intake that did not exceed that of Chow, LF feeding was associated with increased body weight, adipocyte hypertrophy, impaired glucose tolerance and postprandial hyperinsulinemia. Fecal short-chain fatty acids (SCFAs) and branched SCFAs declined, consistent with a reduction in colonic fermentative output. Chronic LF exposure was additionally associated with hepatic and renal lipid accumulation, normoglycemic glycosuria, and podocyte structural alterations. Conclusions: A purified low-fat diet was associated with the same spectrum of gut, liver and kidney alterations as its high-fat counterpart, without excess caloric intake. These findings support an important role for nutrient sources and carbohydrate quality in shaping metabolic health beyond dietary fat content or caloric load alone.
About Me
Degree in Biochemistry,
Currently in the Biomedical Investigation Master's Degree, doing the master thesis
Degree in Biochemistry,
Currently in the Biomedical Investigation Master's Degree, doing the master thesis